HER2-positive (IHC 3+ or ISH-amplified)
A cancer with too much HER2 growth-signal protein, either scored 3+ on the stain or shown to have extra copies of the gene. Once the most aggressive breast cancer subtype, it is now among the most treatable thanks to anti-HER2 drugs.
About 15-20% of breast cancers and a similar share of gastric/GEJ cancers are HER2-positive by ASCO/CAP criteria (IHC 3+, or IHC 2+ with in situ hybridisation amplification). They receive trastuzumab, pertuzumab, T-DM1 and T-DXd in curative and metastatic settings, with response-adapted pathways (KATHERINE, DESTINY-Breast). HER2-low (IHC 1+ or 2+/ISH-negative) and ultralow tumours are not 'positive' but respond to T-DXd, so the category is now a spectrum. HER2 mutations (rather than amplification) in lung cancer are targeted by T-DXd and zongertinib; HER2 amplification also occurs in colorectal, bladder and biliary cancers.
Pages like this
not linked directly; found by shared links- TermDual HER2 blockade
Shares APHINITY, Pertuzumab, Trastuzumab, HER2.
- IdeaRe-test the metastasis, not the old primary, before every change of treatment
Shares Immunohistochemistry (IHC), HER2-low and HER2-ultralow, HER2-positive breast cancer, Non-small-cell lung cancer.
- TrialCLEOPATRA
Shares Pertuzumab, Trastuzumab, HER2, HER2-positive breast cancer.
- TrialHER2CLIMB-05
Shares Pertuzumab, Trastuzumab, HER2-positive breast cancer.
- InstitutionGeorgetown Lombardi Comprehensive Cancer Center
Shares Pertuzumab, Trastuzumab, HER2, HER2-positive breast cancer.
- IdeaCan T-DXd alone cure early HER2-positive disease?
Shares Pertuzumab, Trastuzumab, Trastuzumab deruxtecan, HER2-positive breast cancer.
- TermAmplification
Shares HER2-low and HER2-ultralow, Trastuzumab, Trastuzumab deruxtecan, HER2.
- InstitutionInstituto Alexander Fleming
Shares Trastuzumab, HER2, HER2-positive breast cancer, Non-small-cell lung cancer.